Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
boston blog main
clinical trials
fda
boston top stories
eli lilly
indiana blog main
indiana top stories
national top stories
amgen
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
calcitonin gene-related peptide
chronic migraine
migraine research foundation
national
abbvie
drugs
episodic migraine
eptinezumab
What
fda
10
×
won
approval
drug
new
migraine
class
developed
approved
decades
drugs
eli
friday
late
lilly
medical
medicine
medicines
oral
pain
second
starts
therapeutics
therapy
acute
addresses
agency
aging
aimmune
alkermes
allergy
amgen
announced
antipsychotic
app
arguments
august
awarded
benefits
betting
Language
unset
Current search:
won���t
×
fda
×
@WIRED
1 year ago
The idea that aging might one day be treatable hasn’t yet won over regulators like the FDA, but it has been gaining ground in the field of medical research. 8/9 https://t.co/pkb5sTS9Np
@wired.com
2 years ago
Google Launches a New Medical App—Outside the US
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines